Lucid Diagnostics (LUCD) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MaxCyte (MXCT) has outperformed Lucid Diagnostics (LUCD) over the past year, losing 40.0% versus a loss of 46.7%. Over five years, MXCT leads with a -90.8% price change compared with -93.0% for LUCD. Lucid Diagnostics is the larger company by market cap ($124.1 million vs $105.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUCD | MXCT |
|---|---|---|
| Share price | $0.6501 | $1.02 |
| Market cap | $124.14M | $105.27M |
| 1-day change | +4.27% | -1.92% |
| YTD return | -40.36% | -34.19% |
| 1-year return | -46.71% | -40.00% |
| 5-year return | -93.05% | -90.75% |
| EPS (TTM) | $-0.44 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.63 | $1.87 |
| 52-week low | $0.50 | $0.643 |
| Distance from 52-week high | -60.09% | -45.31% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +515.29% | +302.94% |
| Average volume | 1.35M | 668.82K |
| Shares outstanding | 190.95M | 103.21M |
| Employees | 82 | 91 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Lucid Diagnostics
LUCD stock →Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
Healthcare · Medical Devices · 82 employees
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Healthcare · Medical Devices · 91 employees
LUCD vs MXCT FAQ
Which is bigger, Lucid Diagnostics or MaxCyte?
Lucid Diagnostics (LUCD) is larger, with a market capitalization of $124.14M compared with $105.27M for MaxCyte (MXCT).
Which stock has performed better over the past year, LUCD or MXCT?
MXCT returned -40.00% over the past 12 months, compared with -46.71% for LUCD (price return, excluding dividends). Past performance does not predict future results.
Are Lucid Diagnostics and MaxCyte in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.